![\"Close](\"https:\/\/www.newsbeep.com\/ca\/wp-content\/uploads\/2026\/01\/d41586-026-00220-9_51970264.jpg\"\/)
<\/p>\n <\/p>\n
Guinea-Bissau will implement a universal birth-dose policy for the Hepatitis B vaccine in 2027.Credit: Enrique Lopez-Tapia\/Nature Picture Library\/Alamy<\/p>\n
Public health authorities in Guinea-Bissau say that they have suspended a controversial US-funded hepatitis B vaccine<\/a> study that has raised questions about who has authority over clinical research conducted in Africa. At a press conference held today, officials from Guinea-Bissau\u2019s ministry of health said that the study was being suspended pending a technical and ethical review by its national public health institute. The announcement followed weeks of conflicting statements as to whether or not the trial would proceed. <\/p>\n \u201cThere has been no sufficient coordination in order to take a final decision regarding the study,\u201d said Quinhin Nantote, the minister of public health for Guinea-Bissau. \u201cFaced with this situation, we decided to suspend it.\u201d <\/p>\n Mixed messages<\/p>\n The meeting, convened by the Africa Centres for Disease Control and Prevention (Africa CDC), comes after an official with the organization signalled last week<\/a> that the trial would not proceed. In an email to Nature today, officials at the US Department of Health and Human Services (HHS), a prominent funder of the research, said that the study was still on track, leaving the trial\u2019s status still uncertain.<\/p>\n Hotly anticipated US vaccine meeting ends with confusion \u2014 and a few decisions<\/p>\n <\/a>\u201cThe study is proceeding as planned and we continue to work with our partners to finalize the study\u2019s protocols,\u201d wrote Emily Hilliard, a spokesperson for the HHS. <\/p>\n The continuing row shines a spotlight on long-standing tensions for clinical research trials in Africa. African scientists say that the Guinea-Bissau study shows how political pressure, funding interests and fragmented oversight can push local health priorities aside.<\/p>\n The hepatitis B vaccine trial was designed by researchers at the Bandim Health Project (Projecto de Sa\u00fade) out of the University of Southern Denmark, and funded in part through a US$1.6 million research grant from the US Centers for Disease Control and Prevention, part of the HHS. The study aims to randomize 14,000 newborns in Guinea-Bissau starting in early 2026 to either receive the hepatitis B vaccine at birth or not, before the country\u2019s planned universal birth-dose vaccine policy begins in 2027.<\/p>\n The Bandim researchers have said that the study is a chance to investigate whether the vaccine has broader effects on infant health outcomes.<\/p>\n But several scientists have argued that by randomizing newborns to not receive the vaccine, the trial denies a safe and life-saving intervention to infants in Guinea-Bissau, which has a hepatitis B prevalence of about 19%. The immune systems of newborns are immature and about 90% of people infected at birth go on to develop chronic, lifelong infections which may lead to liver disease and early death.<\/p>\n Researchers who oppose the study argue that it is structured in a way that increases the likelihood of detecting harm from the birth dose, even if that harm is not real or clinically meaningful. \u201cThey\u2019re trying to use African children to prove a case for reducing vaccines in the US,\u201d says Seye Abimbola, a professor of health systems at the University of Sydney in Australia, who researches decolonizing global health. \u201cThat\u2019s problematic.\u201d The United States removed its own recommendations for a birth dose of the hepatitis B vaccine earlier this year<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Guinea-Bissau will implement a universal birth-dose policy for the Hepatitis B vaccine in 2027.Credit: Enrique Lopez-Tapia\/Nature Picture Library\/Alamy…\n","protected":false},"author":2,"featured_media":427472,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[49,48,10696,84,1099,13125,1100,714,66,15019],"class_list":["post-427471","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-ca","tag-canada","tag-ethics","tag-health","tag-humanities-and-social-sciences","tag-medical-research","tag-multidisciplinary","tag-politics","tag-science","tag-vaccines"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/427471","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=427471"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/427471\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/427472"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=427471"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=427471"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=427471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"\"](\"https:\/\/www.newsbeep.com\/ca\/wp-content\/uploads\/2026\/01\/d41586-026-00220-9_51462824.jpg\"\/)
<\/p>\n